Northwestern University IRB: STU00211088
Principal Investigator: Katherine L. Wisner, MD, MS
The Asher Center’s Director, perinatal psychiatrist Dr. Katherine Wisner, is currently conducting research on Seroquel (quetiapine), an FDA approved drug commonly used to treat Mood Disorders. Because women are frequently prescribed quetiapine during their reproductive years for a variety of conditions, the goal of this research study is to understand how the dose of quetiapine should be modified for women who are pregnant. By participating in this study, you can help optimize the quality of care for women who are treated with quetiapine during pregnancy. At your initial visit, you will complete a psychiatric evaluation with Dr. Wisner at no cost to you. Three times in pregnancy and once after birth, you will stay overnight in the clinical research unit and complete assessments to monitor your mood, as well as blood draws to monitor your quetiapine concentration. As compensation, you will receive reimbursement for on-site parking, public transportation, and/or childcare (if applicable); financial compensation of $30 for the initial visit and $250 for every subsequent study visit you complete, for a total of up to $1030; medical consultation with Dr. Katherine Wisner and careful monitoring of your symptoms throughout pregnancy.
Participants will be eligible for the study if they:
- Are between the ages of 18-45 years old
- Are in the first or second trimester of pregnancy
- Are taking a daily dose of Seroquel (quetiapine)
If you are interested in participating or would like to hear more information, please email research coordinator Elizabeth Berman or call 855-99-ASHER.